Altimmune (ALT1) Stock Forecast & Price Target
ALT1 Analyst Ratings
Strong Buy
4Buy1Hold0Sell
Based on 5 analysts giving stock ratings to Altimmune in the past 3 months
ALT1 Stock 12 Month Forecast
Average Price Target
MXN 396.58▲(838.65% Upside)Based on 5 Wall Street analysts offering 12 month price targets for Altimmune in the last 3 months. The average price target is MXN 396.58 with a high forecast of MXN 522.55 and a low forecast of MXN 317.26. The average price target represents a 838.65% change from the last price of MXN 42.25.
Past 12 Months12 Month ForecastDec2025Sep2026
HighMXN 522.55
AverageMXN 396.58
LowMXN 317.26
Highest Price TargetHighestMXN 522.55Average Price TargetMXN 396.58Lowest Price TargetLowestMXN 317.26
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio | H.C. Wainwright | MXN 373.25 | buy | 783.44%Upside | Reiterated | 10/08/26 | ||
| Michael DiFiore | Evercore ISI | MXN 335.93→MXN 317.26 | buy | 650.92%Upside | Reiterated | 09/24/26 | ||
| Eliana Merle | Barclays | MXN 373.25 | buy | 783.44%Upside | Reiterated | 08/13/26 | ||
 Unknown AnalystNot Ranked | Jefferies | MXN 522.55 | buy | 1136.81%Upside | Reiterated | 08/13/26 | ||
| Andy Hsieh | William Blair | ― | hold | ― | Reiterated | 08/12/26 | ||
| Srikripa Devarakonda | Truist Financial | ― | buy | ― | Reiterated | 07/29/26 | ||
| Thomas Smith | Leerink Partners | MXN 186.63 | buy | 341.72%Upside | Reiterated | 07/28/26 | ||
| Jonathan Wolleben | Citizens JMP | MXN 261.28→MXN 205.29 | buy | 385.89%Upside | Reiterated | 05/14/26 | ||
| Corinne Johnson | Goldman Sachs | MXN 18.66→MXN 46.66 | hold | 10.43%Upside | Upgraded | 04/24/26 | ||
| William Wood | B. Riley Securities | MXN 335.93→MXN 242.61 | buy | 474.23%Upside | Reiterated | 03/06/26 | ||
| Boris Peaker | JonesTrading | MXN 130.64 | buy | 209.20%Upside | Initiated | 02/13/26 | ||
| Annabel Samimy | Stifel Nicolaus | ― | buy | ― | Reiterated | 12/19/25 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Patrick Trucchio | 10/08/26 | MXN 373.25 | buy | 783.44%Upside | Reiterated | H.C. Wainwright | ||
| Michael DiFiore | 09/24/26 | MXN 335.93→MXN 317.26 | buy | 650.92%Upside | Reiterated | Evercore ISI | ||
| Eliana Merle | 08/13/26 | MXN 373.25 | buy | 783.44%Upside | Reiterated | Barclays | ||
| Unknown AnalystNot Ranked | 08/13/26 | MXN 522.55 | buy | 1136.81%Upside | Reiterated | Jefferies | ||
| Andy Hsieh | 08/12/26 | ― | hold | ― | Reiterated | William Blair | ||
| Srikripa Devarakonda | 07/29/26 | ― | buy | ― | Reiterated | Truist Financial | ||
| Thomas Smith | 07/28/26 | MXN 186.63 | buy | 341.72%Upside | Reiterated | Leerink Partners | ||
| Jonathan Wolleben | 05/14/26 | MXN 261.28→MXN 205.29 | buy | 385.89%Upside | Reiterated | Citizens JMP | ||
| Corinne Johnson | 04/24/26 | MXN 18.66→MXN 46.66 | hold | 10.43%Upside | Upgraded | Goldman Sachs | ||
| William Wood | 03/06/26 | MXN 335.93→MXN 242.61 | buy | 474.23%Upside | Reiterated | B. Riley Securities | ||
| Boris Peaker | 02/13/26 | MXN 130.64 | buy | 209.20%Upside | Initiated | JonesTrading | ||
| Annabel Samimy | 12/19/25 | ― | buy | ― | Reiterated | Stifel Nicolaus |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Altimmune
3 Months
Success Rate8/19 ratings generated profit
42%
Average Return
-9.46%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of -9.46% per trade.
1 Year
Success Rate10/31 ratings generated profit
32%
Average Return
+6.95%
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 32.26% of your transactions generating a profit, with an average return of +6.95% per trade.
2 Years
Success Rate10/31 ratings generated profit
32%
Average Return
-27.10%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 32.26% of your transactions generating a profit, with an average return of -27.10% per trade.
ALT1 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 6 | 9 | 8 | 7 | 5 |
| Buy | 2 | 3 | 1 | 1 | 0 |
| Hold | 2 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 10 | 14 | 11 | 10 | 6 |
In the current month, ALT1 has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ALT1 average Analyst price target in the past 3 months is 396.58.
ALT1 Financial Forecast
HighMXN -2.07
ConsensusMXN -2.48
LowMXN -2.82
ALT1 Earnings Forecast
Next quarter’s earnings estimate for ALT1 is -MXN 2.48 with a range of -MXN 2.82 to -MXN 2.07. The previous quarter’s EPS was -MXN 2.26. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 0.00
ConsensusMXN 0.00
LowMXN 0.00
ALT1 Sales Forecast
Next quarter’s sales forecast for ALT1 is MXN 0 with a range of MXN 0 to MXN 0. The previous quarter’s sales results were MXN 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ALT1 Stock Forecast FAQ
What is MX:ALT1’s average 12-month price target, according to analysts?
Based on analyst ratings, Altimmune’s 12-month average price target is Mex$396.58.
What is MX:ALT1’s upside potential, based on the analysts’ average price target?
Altimmune has 838.65% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Altimmune a Buy, Sell or Hold?
Altimmune has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Altimmune’s share price target?
The average share price target for Altimmune is Mex$396.58. This is based on 5 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$522.55, and the lowest forecast is Mex$317.26. The average share price target represents a 838.65% increase from the current price of Mex$42.25.
What do analysts say about Altimmune?
Altimmune’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Street analysts.
How can I buy shares of Altimmune?
To buy shares of MX:ALT1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
